Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants ; volume:8 ; number:1 ; day:4 ; month:8 ; year:2023 ; pages:1-4 ; date:12.2023
npj vaccines ; 8, Heft 1 (4.8.2023), 1-4, 12.2023
- Creator
-
Springer, David N.
Bauer, Michael
Medits, Iris
Camp, Jeremy V.
Aberle, Stephan W.
Burtscher, Clemens
Höltl, Eva
Weseslindtner, Lukas
Stiasny, Karin
Aberle, Judith H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-023-00708-9
- URN
-
urn:nbn:de:101:1-2024020112222620302026
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Springer, David N.
- Bauer, Michael
- Medits, Iris
- Camp, Jeremy V.
- Aberle, Stephan W.
- Burtscher, Clemens
- Höltl, Eva
- Weseslindtner, Lukas
- Stiasny, Karin
- Aberle, Judith H.
- SpringerLink (Online service)
Other Objects (12)
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Determinants of spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Determinants of spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Determinants of spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants